Inmed Labs generates revenue primarily from two key sources: Sales of Company Products: This includes the sale of a wide range of pharmaceuticals and cosmetics that are manufactured in-house. Sale of Raw Materials: We also generate income through the sale of raw materials to other businesses in need of quality inputs for their production processes. Cost Structure Our costs are divided into the following categories: Raw Materials: The purchase of raw materials for the production of our pharmaceuticals and cosmetics is a major cost. Packaging Materials: The packaging of products to ensure proper presentation, quality, and safety for consumer use. ... Labour and Overheads: This includes wages for production staff and associated overhead costs such as rent, electricity, water, and other office-related expenses. Sales and Marketing Overheads: Costs associated with advertising, promoting, and selling our products, including the salaries of the sales and marketing team and other promotional activities. Expected Annual Revenue After $15 Million Investment With the planned $15 million investment, we anticipate a significant increase in both production capacity and market share, which will result in a growth in annual revenue. The investment will help us to: Increase Output: With $5 million allocated for the purchase of raw materials, we will be able to increase production volume, thereby allowing us to meet the rising demand for our products and generate higher revenue from product sales. Expand Market Reach: The $2 million allocated for expanding the workforce and marketing efforts will enable us to enhance our sales activities, penetrate new markets, and boost product visibility, resulting in higher sales revenue. Improve Quality Standards: The $5 million investment for upgrading the factory to GMP standards will help us to produce higher quality products that meet international standards, allowing us to command better prices and enter more competitive markets. Operational Efficiency: The $3 million for working capital will ensure smooth day-to-day operations, improving cash flow and reducing disruptions in production and sales. Given these expansions, we estimate that the expected annual revenue will grow by 30%-50% in the first year post-investment. This would translate to an approximate increase in revenue of $7.5 million to $12 million, depending on market conditions, sales execution, and demand for our products. Revenue Timeline Year 1 (Post-Investment): We expect to see an initial 20%-30% increase in revenue as we ramp up production, expand our workforce, and start marketing campaigns. The focus will be on scaling up and securing market penetration. Year 2 and Beyond: The full effect of the $15 million investment should be realized within the second year. By this point, we anticipate revenue growth to stabilize at a 30%-50% increase over pre-investment levels. As production capacity increases and our product line expands, revenue will continue to rise steadily. Read more

In order to capitalize on the growing demand for our products and expand our market presence, we are seeking $15 million in funding. The funds will be utilized as follows: $5 million for the purchase of raw materials to increase product output and meet growing consumer demand. $5 million for upgrading our manufacturing facility to meet Good Manufacturing Practices (GMP) standards, ensuring the highest quality and regulatory compliance. $2 million to expand our production workforce and enhance our sales and marketing efforts, including the recruitment and training of new staff to support growth. $3 million for working capital, ensuring smooth ... and effective management of day-to-day expenses. This funding will enable Inmed Labs to meet the increasing demand for our products, strengthen our market position, and continue developing innovative solutions that address critical health and wellness needs. We already have some types of equipment and packaging materials. The products to be manufactured have already been designed and comprise capsules and syrups. These will be added to the already-in-the-market disinfectant solutions. Read more

Target Market Our target market consists of health-conscious consumers seeking safe, effective, and affordable solutions to everyday health and wellness challenges. Key segments include: Health-Conscious Individuals: Consumers looking for effective, non-prescription solutions to common ailments such as coughs, colds, pain relief, and skin care. They prefer natural or herbal remedies and are keen to avoid synthetic drugs and the potential side effects they bring. Women and Skincare Enthusiasts: Women, especially those in the age range of 18-45, represent a key demographic for our cosmetics line. This segment is actively seeking products that provide solutions for skin issues like stretch marks, ... spots, and pigmentation, with a preference for products that are both effective and affordable. Families and General Consumers: Families seeking affordable and reliable over-the-counter medicines for common health issues such as colds, coughs, or mild pain. Our affordable pricing and effective formulations appeal to this broad customer base. Eco-Conscious and Natural Product Consumers: There is a growing segment of consumers who are environmentally conscious and prefer natural, sustainable products. Our products that emphasize natural ingredients, such as Nivercoff, which is made from natural components, cater to this trend. Market Opportunities Expansion into New Markets: As demand for natural and effective products grows, Inmed Labs can expand its reach into international markets where consumers are looking for alternatives to traditional pharmaceutical and cosmetic products. Product Line Expansion: Inmed Labs has a pipeline of new products, such as low-dose painkillers, dewormers, and natural health capsules. These products can capture additional market share in both the pharmaceutical and wellness sectors. Strategic Partnerships: Collaborating with other manufacturers, distributors, and retail chains could enhance our market presence and broaden distribution channels, both locally and internationally. Read more

Inmed Labs is led by Sammy Opiyo, a pharmacist with over 30 years of experience in the pharmaceutical industry. Under his leadership, the company has built a strong team that includes a Managing Director, CFO, Production Manager, Sales and Marketing Director, Head of Research and Development (R&D), and Sales and Marketing staff. Each team member brings specialized expertise, from financial management and operational efficiency to product development and market strategy. Together, they ensure that Inmed Labs continues to innovate and produce high-quality pharmaceutical and cosmetic products, driving the company’s growth and market expansion.